Active, Not Recruiting
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy - CV027-010
Mis à jour:
18 décembre, 2025
|
ClinicalTrials.gov
Résumé imprimable
Détails de l’essai
-
Phase 3
Phase
-
Sexe(s)
-
12-17
Tranche d’âge
-
Active, Not Recruiting
Options de traitement
Principaux critères d’éligibilité
Inclusion Criteria: - Diagnosis of HCM - Presence of LVOT obstruction - Presence of symptoms Exclusion Criteria: - Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction - Evidence of LVEF <50% in prior 6 months - Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase) Other protocol-defined Inclusion/Exclusion criteria apply.